Detection of Genetic Abnormalities in Cancer Cells Using Bio-Plex Immunoassays

Introduction
Receptor tyrosine kinases initiate a tightly controlled cell-signaling network that regulates multiple biological processes. Aberrant activation of such networks plays significant roles in both development and treatment of a variety of cancers (Amann et al. 2005). Genetic abnormalities can further deregulate these networks and confer altered responses to treatment drugs. For example, mutations in the epidermal growth factor receptor (EGFR) gene can lead to either increased sensitivity or resistance to EGFR-targeted drugs. Likewise, mutations within the Bcr-Abl gene abolish responsiveness to Gleevec (imatinib mesylate, Novartis) treatment in chronic myelogenous leukemia (CML). Assays that can detect such mutations in patient samples would facilitate selection of the optimal treatment regimen and enable monitoring of the cancer during therapy.

We developed two sets of capture and detection antibodies specific to the L858R point mutation in EGFR and to Bcr-Abl translocations. In this study, we demonstrate specificity and, for Bcr-Abl, limits of detection of these aberrations in cancer cells. We use Bio-Plex bead-based immunoassays and western blotting for comparison.

Methods
Bio-Plex Assays
Bio-Plex immunoassays detecting the L858R point mutation in EGFR and fusion proteins resulting from translocations of the Bcr-Abl genes were developed. The EGFR mutation assay was developed using a capture antibody reactive with EGFR regardless of its mutation status, and a detection antibody specific for the aberrant form of the receptor (Figure 1). Bcr-Abl was captured with an antibody to Bcr and detected with anti-c-Abl antibody. Cell Signaling Technology, Inc. provided all antibodies.

Fig. 1. Method of detection of mutated EGFR (top) and translocated Bcr-Abl (bottom) using Bio-Plex bead-based immunoassays. In each case, detection requires two specific antibodies: one to capture total protein on the bead, the other to detect the specific abnormality. Antibody pairs were developed to detect EGFR mutation at L858R and Bcr-Abl fusion proteins of varying lengths. Figure is not drawn to scale.
Reactions were performed in 96-well, filter-bottomed plates according to the Bio-Plex phosphoprotein detection instruction manual. Briefly, 2,500 beads coated with the appropriate capture antibody were added to each well in the plate and incubated overnight with lysates from one of eight cell lines obtained from American Type Culture Collection (ATCC) (Table 1). Cells were homogenized by sonication in cell lysis buffer. Following washing, detection antibodies were added and the plates incubated for 30 min. The beads were then washed and incubated for 5 min in streptavidin R-conjugated phycoerythrin. The beads were washed again and analyzed using the Bio-Plex system array reader. Western blot analyses of identically treated cell lysates were performed following protein separation by SDS-PAGE and transfer to nitrocellulose membranes.

Chromosomal abnormalities can create a variety of Bcr-Abl translocations. Depending on translocation length, this results in Bcr-Abl fusion proteins of different composition (Figure 2), which can present a challenge to detection by antibodies. To test our antibody performance, we examined three cell lines expressing differing fusion proteins: e1a2, b2a2, and b3a2, as well as c-Abl alone and Brc-Abl negative as controls (see Table 1 for names of cell lines).

**Results and Discussion**

**EGFR Mutation**

The L858R mutant-specific antibody pair preferentially recognized the L858R point mutation in EGFR (Figure 3). The results corroborated western blotting analysis using the L858R mutant-specific antibody.

**Bcr-Abl Chromosomal Translocations**

Limit of detection, as determined by the minimum detectable number of cells/ml, was calculated using K-562 lysates. The Bio-Plex assays reliably detected Bcr-Abl at levels as low as 165 cells/ml (Figure 4A), about 4 orders of magnitude more sensitive than our results for western blotting (~2 x 10^6 cells/ml, Figure 4B). The Bio-Plex assay detected Bcr-Abl at densities from 165 cells/ml to 5 x 10^6 cells/ml.

The antibody pair used in the Bio-Plex immunoassay detected all three Bcr-Abl isoforms tested (Figure 5). Western blot analysis using a Bcr-specific antibody yielded similar results.

<table>
<thead>
<tr>
<th>Trait</th>
<th>Cell Line</th>
<th>Cancer Type</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EGFR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wild type</td>
<td>NCI-H358</td>
<td>NSCLC*</td>
</tr>
<tr>
<td>L858R point mutation</td>
<td>NCI-H1975</td>
<td>NSCLC</td>
</tr>
<tr>
<td><strong>Bcr-Abl</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No translocation</td>
<td>THP-1</td>
<td>AML*</td>
</tr>
<tr>
<td>b2a2**</td>
<td>T1</td>
<td>CML*</td>
</tr>
<tr>
<td>b3a2**</td>
<td>K-562</td>
<td>CML</td>
</tr>
<tr>
<td>e1a2**</td>
<td>SUP-B15</td>
<td>CML</td>
</tr>
<tr>
<td>c-Abl positive</td>
<td>A-204</td>
<td>Rhabdomyosarcoma</td>
</tr>
<tr>
<td>EGFR-wild; Bcr-Abl-normal</td>
<td>HeLa</td>
<td>Cervical cancer</td>
</tr>
</tbody>
</table>

* NSCLC, non-small cell lung cancer; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia.
** See Figure 2.

**EGFR Mutation**

![Fig. 3. Detection of the L858R point mutation in EGFR protein in lysates from three cell lines. Line NCI-H1975 harbors the mutation; NCI-H358 and HeLa lines are wild type. Bio-Plex assays (top) and western blotting (bottom) yielded similar results.](image)

**Bcr-Abl Chromosomal Translocations**

![Fig. 2. Bcr-Abl fusion protein isoforms tested in this study. Translocation can result in fusion proteins containing differing Bcr and Abl lengths. Three such isoforms, b2a2, b3a2, and e1a2, were tested using a single antibody pair.](image)
Conclusions

Antibody pairs reactive with EGFR point mutation demonstrated suitable specificity for use in disease management and monitoring.

The Bio-Plex immunoassay for the detection of Bcr-Abl translocations was more sensitive than western blotting by about 4 orders of magnitude. The Bcr-Abl specific antibody pair recognized all three Bcr-Abl isoforms tested.

We successfully developed assays capable of detecting genetic abnormalities in cancer cells using specific antibodies and the Bio-Plex platform. The ability to multiplex genetic analysis will enable the precise and rapid evaluation of the mutational status of research and clinical tissue samples.

Reference


ATCC is a trademark of American Type Culture Collection. Cell Signaling Technology and the Cell Signaling Technology logo are trademarks of Cell Signaling Technology, Inc. Gleevec is a trademark of Novartis AG. The Bio-Plex suspension array system includes fluorescently labeled microspheres and instrumentation licensed to Bio-Rad Laboratories, Inc. by the Luminex Corporation.

Information in this tech note was current as of the date of writing (2007) and not necessarily the date this version (rev A, 2007) was published.

Fig. 4. Limits of detection for Bcr-Abl translocations in K-562 cells. A, Bio-Plex assays detected translocations at concentrations as low as 165 cells/ml; B, upper limit of detection for Bio-Plex assays (upper scan) was 5 x 10^6 cells/ml; western blotting (lower image) lower limit of detection was 2 x 10^6 cells/ml.

Fig. 5. Bio-Plex assay (top) and western blot (bottom) detection of three Bcr-Abl isoforms. The isoforms (see Figure 2) were detected in three CML cell lines and absent from three control cell lines.